Cargando…

Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022

BACKGROUND: Health care workers (HCW) have a higher exposure to SARS-CoV-2 virus than other professionals and to protect both HCW and patients, HCW have been prioritized for vaccination against SARS-CoV-2 in many countries. Estimating the COVID-19 vaccine effectiveness among HCW is important to prov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langlete, Petter, Tesli, Martin, Veneti, Lamprini, Starrfelt, Jostein, Elstrøm, Petter, Meijerink, Hinta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169571/ https://www.ncbi.nlm.nih.gov/pubmed/37211454 http://dx.doi.org/10.1016/j.vaccine.2023.05.022

Ejemplares similares

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
por: Veneti, Lamprini, et al.
Publicado: (2023)

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
por: Seppälä, Elina, et al.
Publicado: (2021)

Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022
por: Veneti, Lamprini, et al.
Publicado: (2022)

Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021
por: Starrfelt, Jostein, et al.
Publicado: (2022)

High vaccine effectiveness against coronavirus disease 2019 (COVID-19) and severe disease among residents and staff of long-term care facilities in Norway, November 2020–June 2021
por: Starrfelt, Jostein, et al.
Publicado: (2022)

A standardised protocol for relative SARS-CoV-2 variant severity assessment, applied to Omicron BA.1 and Delta in six European countries, October 2021 to February 2022
por: Nyberg, Tommy, et al.
Publicado: (2023)

No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway
por: Veneti, Lamprini, et al.
Publicado: (2022)

Evaluation of the pilot wastewater surveillance for SARS-CoV-2 in Norway, June 2022 – March 2023
por: Amato, Ettore, et al.
Publicado: (2023)

COVID-19 Booster Vaccination in the U.S. Military, August 2021–January 2022
por: Winkler, Erin L., et al.
Publicado: (2023)

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021
por: Brandal, Lin T., et al.
Publicado: (2021)

Comparative hospitalization risk for SARS‐CoV‐2 Omicron and Delta variant infections, by variant predominance periods and patient‐level sequencing results, New York City, August 2021–January 2022
por: Greene, Sharon K., et al.
Publicado: (2022)

Comprehensive Contact Tracing, Testing and Sequencing Show Limited Transmission of SARS-CoV-2 between Children in Schools in Norway, August 2020 to May 2021
por: Winje, Brita Askeland, et al.
Publicado: (2021)

First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022
por: Maisa, A., et al.
Publicado: (2022)

Experience with open schools and preschools in periods of high community transmission of COVID-19 in Norway during the academic year of 2020/2021
por: Stebbings, Sara, et al.
Publicado: (2022)

Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
por: Suarez Castillo, Milena, et al.
Publicado: (2022)

Minimal transmission of SARS-CoV-2 from paediatric COVID-19 cases in primary schools, Norway, August to November 2020
por: Brandal, Lin T, et al.
Publicado: (2021)

Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022
por: Hoeve, Christina E, et al.
Publicado: (2023)

Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022
por: van Iersel, Senna C.J.L., et al.
Publicado: (2023)

Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022
por: Stefanelli, Paola, et al.
Publicado: (2022)

Effectiveness of MRNA booster vaccine among healthcare workers in New York City during the Omicron surge, December 2021 to January 2022
por: Robilotti, Elizabeth V., et al.
Publicado: (2022)

Pseudomonas aeruginosa countrywide outbreak in hospitals linked to pre-moistened non-sterile washcloths, Norway, October 2021 to April 2022
por: Gravningen, Kirsten, et al.
Publicado: (2022)

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
por: Andersson, Niklas Worm, et al.
Publicado: (2023)

Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants
por: Jalali, Neda, et al.
Publicado: (2022)

The fight to keep resistance at bay, epidemiology of carbapenemase producing organisms (CPOs), vancomycin resistant enterococci (VRE) and methicillin resistant Staphylococcus aureus (MRSA) in Norway, 2006 - 2017
por: Elstrøm, Petter, et al.
Publicado: (2019)

Compliance with water advisories after water outages in Norway
por: Hyllestad, Susanne, et al.
Publicado: (2019)

Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022
por: Kahn, Fredrik, et al.
Publicado: (2022)

Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022
por: Eggink, Dirk, et al.
Publicado: (2022)

Impact of SARS-CoV-2 Omicron and Delta variants in patients requiring intensive care unit (ICU) admission for COVID-19, Northern Italy, December 2021 to January 2022
por: Piralla, Antonio, et al.
Publicado: (2023)

A tale of two STs: molecular and clinical epidemiology of MRSA t304 in Norway 2008–2016
por: Enger, Hege, et al.
Publicado: (2021)

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
por: Thompson, Mark G., et al.
Publicado: (2022)

Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022
por: Sentís, Alexis, et al.
Publicado: (2022)

Factors associated with COVID-19 vaccine uptake in adolescents: a national cross-sectional study, August 2021–January 2022, England
por: Aiano, Felicity, et al.
Publicado: (2023)

Monitoring COVID‐19 vaccine effectiveness against COVID‐19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022
por: Kislaya, Irina, et al.
Publicado: (2023)

Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses
por: Andersson, Niklas Worm, et al.
Publicado: (2023)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

COVID-19 Delta variants—Current status and implications as of August 2021
por: Yu, Flora, et al.
Publicado: (2021)

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
por: Ferdinands, Jill M., et al.
Publicado: (2022)

Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 – February 2022)
por: Petrone, Daniele, et al.
Publicado: (2023)

Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022
por: Lambrou, Anastasia S., et al.
Publicado: (2022)

Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study
por: Auvigne, Vincent, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rg3jktt2a6bk2odio81jjngqgh